Country websites
Australia (Ascent)
Australia (Spirit)
Austria
Belgium
Bosnia and Herzegovina
Bulgaria
Brazil (Erowlabs)
Canada (Cobalt)
Canada (Watson)
China
Czech Republic
Denmark
Finland
France (Arrow)
Germany
Germany (Arrow)
Greece (Alet)
Hong Kong
Hong Kong (DHA)
Hungary
Iceland
Indonesia
Ireland
Ireland (Arrow)
Japan
Lithuania
Luxemburg
Malaysia (DHA)
Malta
Mongolia
New Zealand (Arrow)
Netherlands
Norway
Poland
Poland (Arrow)
Portugal
Romania
Russia
Serbia
Singapore (DHA)
Spain
Sweden
Sweden (Arrow)
Switzerland
Turkey
Ukraine
United Kingdom
United Kingdom (Arrow)
United Kingdom (Arrow)
Vietnam (DHA)
About Actavis
Company Profile
CEO Message
Mission / Culture
Executive Leadership
Global Locations
Facilities
Commercial
North America
Europe
Asia Pacific
Global Business
Actavis Pharma
North America
Europe
Asia & MEA
Actavis Specialty Brands
US
Canada & LATAM
Biosimilars
Distribution
Anda
PractRx
Intellogics
Products
R&D
R&D Sites
Generics R&D
Biosimilars R&D
Brands R&D
Therapeutic Classes
Generics
Biosimilars
Brands
Drug Safety
Quality
U.S. Product Database
Investors
Press Releases
Financial Information
SEC Filings
Annual Reports
Quarterly Results
2013 Proxy Materials
Corporate Fact Sheet
Corporate Governance
Executive Officers and Directors
Committee Composition
Committee Charters
Code of Conduct
Governance Guidelines
Insider Transactions
Actavis Compliance Program
Events and Presentations
Stock Information
Stock Quote
Stock Chart
Historical Price Lookup
Investment Calculator
Shareholder Services
FAQs
Information Requests
E-mail Alerts
Analyst Coverage
Responsibility
Environmental
Employees
Facilities & Manufacturing
Partners
Community
Media
Corporate Profile
Press releases
Resources
Careers
Working at Actavis
Culture
Benefits
Career Opportunities
University
On-Campus Recruiting
Internships & Programs
Recent Graduates
Applying to Actavis in the US
Contact Us
SEC Filings
Investors
>
SEC Filings
Form 8-K
ACTAVIS, INC. filed this
Form 8-K
on 01/25/2013
Document Outline
Entire Document (1309.5 KB)
Subdocument 1 - 8-K - FORM 8-K
Page 1 - UNITED STATES
Page 2 - Item 1.01. Entry into a Material Definitive Agreement.
Page 3 - Item 2.01. Completion of Acquisition or Disposition of Assets
Page 4 - Item 9.01. Financial Statements and Exhibits.
Page 5 - N/A
Page 6 - EXHIBIT INDEX
Subdocument 2 - EX-2.1 - STOCK PURCHASE AGREEMENT, DATED AS OF JANUARY 19, 2013
Page 1 - Exhibit 2.1
Page 2 - Private and confidential
Page 3 - SHARE PURCHASE AGREEMENT
Page 4 - Private and confidential
Page 5 - Private and confidential
Page 6 - Private and confidential
Page 7 - Private and confidential
Page 8 - Private and confidential
Page 9 - Private and confidential
Page 10 - Private and confidential
Page 11 - Private and confidential
Page 12 - Private and confidential
Page 13 - Private and confidential
Page 14 - Private and confidential
Page 15 - Private and confidential
Page 16 - Private and confidential
Page 17 - Private and confidential
Page 18 - Private and confidential
Page 19 - Private and confidential
Page 20 - Private and confidential
Page 21 - Private and confidential
Page 22 - Private and confidential
Page 23 - Private and confidential
Page 24 - Private and confidential
Page 25 - Private and confidential
Page 26 - Private and confidential
Page 27 - Private and confidential
Page 28 - Private and confidential
Page 29 - Private and confidential
Page 30 - Private and confidential
Page 31 - Private and confidential
Page 32 - Private and confidential
Page 33 - Private and confidential
Page 34 - Private and confidential
Page 35 - Private and confidential
Page 36 - Private and confidential
Page 37 - Private and confidential
Page 38 - Private and confidential
Page 39 - Private and confidential
Page 40 - Private and confidential
Page 41 - Private and confidential
Page 42 - Private and confidential
Page 43 - Private and confidential
Page 44 - Private and confidential
Page 45 - Private and confidential
Page 46 - Private and confidential
Page 47 - Private and confidential
Page 48 - Private and confidential
Page 49 - Private and confidential
Page 50 - Private and confidential
Page 51 - Private and confidential
Page 52 - Private and confidential
Page 53 - Private and confidential
Page 54 - Private and confidential
Page 55 - Private and confidential
Page 56 - Private and confidential
Page 57 - Private and confidential
Page 58 - Private and confidential
Page 59 - Private and confidential
Page 60 - Private and confidential
Page 61 - Private and confidential
Page 62 - Private and confidential
Page 63 - Private and confidential
Page 64 - Private and confidential
Page 65 - Private and confidential
Page 66 - Private and confidential
Page 67 - Private and confidential
Page 68 - Private and confidential
Page 69 - Private and confidential
Page 70 - Private and confidential
Page 71 - Private and confidential
Page 72 - Private and confidential
Page 73 - Private and confidential
Page 74 - Private and confidential
Page 75 - Private and confidential
Page 76 - Private and confidential
Page 77 - Private and confidential
Page 78 - Private and confidential
Page 79 - Private and confidential
Page 80 - Private and confidential
Page 81 - Private and confidential
Page 82 - Private and confidential
Page 83 - Private and confidential
Page 84 - Private and confidential
Page 85 - Private and confidential
Page 86 - Private and confidential
Page 87 - Private and confidential
Page 88 - Private and confidential
Page 89 - Private and confidential
Page 90 - Private and confidential
Page 91 - Private and confidential
Page 92 - Private and confidential
Page 93 - Private and confidential
Page 94 - Private and confidential
Page 95 - Private and confidential
Page 96 - Private and confidential
Page 97 - Private and confidential
Page 98 - Private and confidential
Page 99 - Private and confidential
Page 100 - Private and confidential
Page 101 - Private and confidential
Page 102 - Private and confidential
Page 103 - Private and confidential
Page 104 - Private and confidential
Page 105 - Private and confidential
Page 106 - Private and confidential
Page 107 - Private and confidential
Page 108 - Private and confidential
Page 109 - Private and confidential
Page 110 - Private and confidential
Page 111 - Private and confidential
Page 112 - Private and confidential
Page 113 - Private and confidential
Page 114 - Private and confidential
Page 115 - Private and confidential
Page 116 - Private and confidential
Page 117 - Private and confidential
Page 118 - Private and confidential
Page 119 - Private and confidential
Page 120 - Private and confidential
Page 121 - EXHIBIT 4
Page 122 - Private and confidential
Page 123 - Private and confidential
Page 124 - Private and confidential
Page 125 - Private and confidential
Page 126 - Private and confidential
Page 127 - Private and confidential
Page 128 - Private and confidential
Page 129 - Private and confidential
Page 130 - Private and confidential
Page 131 - Private and confidential
Page 132 - Private and confidential
Page 133 - Private and confidential
Page 134 - Private and confidential
Page 135 - Private and confidential
Page 136 - Private and confidential
Page 137 - Private and confidential
Page 138 - Private and confidential
Page 139 - Private and confidential
Page 140 - Private and confidential
Page 141 - Private and confidential
Page 142 - Private and confidential
Page 143 - Private and confidential
Page 144 - Private and confidential
Page 145 - Private and confidential
Page 146 - Private and confidential
Page 147 - Private and confidential
Page 148 - Private and confidential
Page 149 - Private and confidential
Page 150 - Private and confidential
Page 151 - Private and confidential
Subdocument 3 - EX-99.1 - PRESS RELEASE ISSUED BY ACTAVIS, INC. (FORMERLY WATSON PHARMACEUTICALS, INC.)
Page 1 - Exhibit 99.1
Page 2 - Near-Term Product Opportunities
Page 3 - Mid Stage Development Candidate
Page 4 - About Uteron
Page 5 - N/A
Investors
Press Releases
Financial Information
SEC Filings
Annual Reports
Quarterly Results
2013 Proxy Materials
Corporate Fact Sheet
Corporate Governance
Executive Officers and Directors
Committee Composition
Committee Charters
Code of Conduct
Governance Guidelines
Insider Transactions
Actavis Compliance Program
Events and Presentations
Stock Information
Stock Quote
Stock Chart
Historical Price Lookup
Investment Calculator
Shareholder Services
FAQs
Information Requests
Investor Kit
E-mail Alerts
Analyst Coverage
Tool Kit
Actavis Capabilities Brochure
Latest Annual Report
Latest 10-K
Latest 10-Q
Latest Earnings Press Release
2013 Proxy Materials
Print Page
E-mail Page
RSS Feeds
E-mail Alerts
Contact Information
Electronic Enrollment
Actavis Shareholders: Sign up to receive your proxy materials
Click Here >>
Click Here
to print or vote your proxy materials.